Yi‐Ting Wang
A5061973060- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Neurological Disease Mechanisms and Treatments
- Functional Brain Connectivity Studies
- Advanced Neuroimaging Techniques and Applications
- Advanced MRI Techniques and Applications
- Medical Imaging Techniques and Applications
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Neurological Disorders and Treatments
- Cancer-related cognitive impairment studies
- Health, Environment, Cognitive Aging
- Lanthanide and Transition Metal Complexes
- S100 Proteins and Annexins
- Frailty in Older Adults
- COVID-19 and Mental Health
- Renal and related cancers
- Neuroscience and Neuropharmacology Research
- Genetics, Aging, and Longevity in Model Organisms
- Digestive system and related health
- Hearing Loss and Rehabilitation
- MRI in cancer diagnosis
- Tryptophan and brain disorders
- Mitochondrial Function and Pathology
- Diabetes Treatment and Management
McGill University
2021-2025
Montreal Neurological Institute and Hospital
2023-2025
Douglas Mental Health University Institute
2022-2024
Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal
2022-2024
Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean
2022-2024
McGill University Health Centre
2020-2024
Douglas College
2021-2023
Institute of Chemistry, Academia Sinica
2019
We set out to identify tau PET-positive (A+T+) individuals among amyloid-beta (Aβ) positive participants using plasma biomarkers.
Abstract Recently approved anti-amyloid immunotherapies for Alzheimer’s disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. Blood-based biomarkers promise to reduce the need PET CSF testing; however, their interpretation at individual level and circumstances requiring confirmatory testing are poorly understood. Individual-level diagnostic test results requires knowledge prevalence in relation...
Abstract The progression of PET-based Braak stages correlates with cognitive deterioration in aging and Alzheimer’s disease. Here, we investigate the association between functional impairment assess whether staging predicts a longitudinal decline performance activities daily living. In this cohort study, evaluated cognitively unimpaired individuals mild or disease dementia. Participants underwent [18F]MK6240 tau-PET, were assigned stage at baseline followed for mean (SD) 1.97 (0.66) years....
<title>Abstract</title> Tau pathology spreads and accumulates during Alzheimer’s disease (AD), but the relationship between these processes throughout progression remains unclear. We assessed spatiotemporal dynamics of tau spreading accumulation using tau-PET data from 1,175 participants in TRIAD ADNI cohorts, including 277 with 2-year follow-ups. standardized uptake value ratios (SUVR) indexed load, while spatial extent tauopathy (SEOT; proportion abnormal voxels) measured spread....
Plasma phosphorylated tau biomarkers open unprecedented opportunities for identifying carriers of Alzheimer's disease pathophysiology in early stages using minimally invasive techniques. p-tau are believed to reflect phosphorylation and secretion. However, it remains unclear what extent the magnitude plasma abnormalities reflects neuronal network disturbance form cognitive impairment. To address this question, we included 103 cognitively unimpaired elderly 40 impaired, amyloid-β positive...
G protein-coupled estrogen receptor-1 (GPER), a member of the receptor (GPCR) superfamily, mediates estrogen-induced proliferation normal and malignant breast epithelial cells. However, its role in cancer stem cells (BCSCs) remains unclear. Here we showed greater expression GPER BCSCs than non-BCSCs three patient-derived xenografts ER
Abstract Females are disproportionately affected by dementia due to Alzheimer's disease. Despite a similar amyloid-β (Aβ) load, higher load of neurofibrillary tangles (NFTs) is seen in females than males. Previous literature has proposed that Aβ and phosphorylated-tau (p-tau) synergism accelerates tau tangle formation, yet the effect biological sex this process been overlooked. In observational study, we examined longitudinal neuroimaging data from TRIAD ADNI cohorts Canada USA,...
Abnormal mitochondrial metabolism has been described in the Alzheimer's disease (AD) brain. However, relationship between AD pathophysiology and key processes remains elusive. The purpose of this study was to investigate whether complex I dysfunction is associated with amyloid aggregation or glucose brain atrophy patients mild using positron emission tomography (PET).Amyloid- tau-positive symptomatic clinical dementia rating 0.5 1 (N = 30; mean age ± standard deviation: 71.8 7.6 years)...
Abstract The apolipoprotein E gene (APOE) is the most important genetic risk factor for sporadic Alzheimer disease, with ε4 allele being associated increased cerebral amyloid-β and tau pathologies. Although APOE has been suggested to have a stronger effect in women as compared men, there lack of comprehensive assessment on how interactive sex modulates regional vulnerability accumulation. We previously shown APOE, yet difference was not specifically addressed. In this study, we leveraged PET...
Abstract Background The high prevalence of Alzheimer’s dementia in females have long puzzled researchers the field. Despite similar amyloid levels, show higher load neurofibrillary tangles (NFTs). Previous literature proposed that amyloid‐β (Aβ) and phosphorylated tau (p‐tau) synergism accelerates biomarker abnormalities. However, it remains to be answered whether this is driving force behind faster progression females. overarching goal study wa investigate aggregates differentially impose...
[18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. However, no have yet published data on longitudinal Aβ accumulation measured with [18F]AZD4694.
Blood-based biomarkers have been revolutionizing the detection, diagnosis and screening of Alzheimer's disease. Specifically, phosphorylated-tau variants (p-tau181, p-tau217 p-tau231) are promising for identifying disease pathology. Antibody-based assays such as single molecule arrays immunoassays powerful tools to investigate pathological changes indicated by blood-based studied extensively in research field. A novel proteomic technology-NUcleic acid Linked Immuno-Sandwich Assay...
Abstract Background Recent evidence indicated that cognitive impairment is more closely associated with the spatial extent of tauopathy (SEOT) than tau load. It remains unclear whether this also true for other markers Alzheimer’s disease (AD) severity, such as fluid levels phosphorylated (pTau). Here, we compared link between pTau and SEOT load in brain, assessed by PET. Method We studied individuals across aging AD continuum or non‐AD neurodegenerative diseases from TRIAD ADNI cohorts....
Abstract Background Increased uptake on Tau positron‐emission tomography (PET) is sometimes observed in the absence of amyloid β accumulation. This A‐T+ PET profile might represent primary age‐related tauopathy (PART), an β‐independent 3R/4R aging brains. Although individuals have been shown to follow a different cognitive trajectory compared A‐T‐ and A+T+ individuals, it remains unknown how they differ terms plasma biomarkers. Here, we aim characterize biomarkers individuals. Method...
Abstract Background Tau burden has been found to be involved in brain atrophy during aging, especially regions such as the parahippocampal gyrus. However, how tau levels at baseline are associated with trajectories of accumulation, cortical thinning and cognitive impairment remains poorly understood. The goal this study was assess rate change patients between Tau+ Tau‐ patients. We also aimed determine if status or accumulation interacted regions, leading an increased cognition. Method...
Abstract Background It has been proposed that microglia release of proinflammatory factors reactive to amyloid plaques constitutes an early event leading tau pathology. Here, we assessed how the rate progression tau‐PET and change in plasma pTau217 are affected by baseline levels amyloid‐β neuroinflammation. Methods We included 93 individuals from TRIAD cohort: 11 young individuals, 57 cognitively unimpaired elderlies, 15 with mild cognitive impairment 10 Alzheimer’s Disease....
Abstract Background Tau‐PET tracers allow for in vivo Braak staging of individuals the Alzheimer’s disease (AD) continuum. The impact tracers’ characteristics using tau‐PET remains unclear. Therefore, we performed a head‐to‐head comparison first‐ and second‐generation tracers. Method We assessed 51 cognitively unimpaired (CU) 49 impaired participants (mean [SD] age 69.4 [7.5] years) with at least two ligands ([ 18 F]MK6240, [ F]AV1451, and/or F]RO948) McGill University, as part HEAD study....
Abstract Background Alzheimer's disease (AD) disproportionately impacts females, who exhibit a higher tau load compared to males. Existing literature suggests that biological sex may alter the impact of APOE on pathology in AD. Nevertheless, genetic factors contributing differences AD pathology, beyond influence APOE, have been minimally investigated. Methods This study included 2 well‐characterized cohorts: Translational Biomarkers Aging and Dementia (TRIAD, n=359) cohort ADNI (n=283). All...
Abstract Background Blood‐based biomarkers have been revolutionizing the detection, diagnosis and screening of Alzheimer’s disease (AD). Antibody‐based immunoassays are powerful tools to investigate pathological changes indicated by blood‐based studied extensively in AD research. A novel proteomic technology ‐ NUcleic acid Linked Immuno‐Sandwich Assay (NULISA) – was developed improve sensitivity traditional proximity ligation assays offer a comprehensive outlook for protein neurodegenerative...
Abstract Background Tau‐PET tracers allow for in vivo Braak staging of individuals the Alzheimer’s disease (AD) continuum. The impact tracers’ characteristics using tau‐PET remains unclear. Therefore, we performed a head‐to‐head comparison first‐ and second‐generation tracers. Method We assessed 51 cognitively unimpaired (CU) 49 impaired participants (mean [SD] age 69.4 [7.5] years) with at least two ligands ([18F]MK6240, [18F]AV1451, and/or [18F]RO948) McGill University, as part HEAD study....
Abstract Background Recent evidence indicated that cognitive impairment is more closely associated with the spatial extent of tauopathy (SEOT) than tau load. It remains unclear whether this also true for other markers Alzheimer’s disease (AD) severity, such as fluid levels phosphorylated (pTau). Here, we compared link between pTau and SEOT load in brain, assessed by PET. Method We studied individuals across aging AD continuum or non‐AD neurodegenerative diseases from TRIAD ADNI cohorts....
Abstract Background Intracellular accumulation of tau tangles in the brain is one most prominent manifestations Alzheimer’s disease (AD). Progression thereof across AD stages has specific temporal and spatial patterns, wherein time informative space vice versa. Here we introduce a novel method, Manifold Component Analysis (MCA), to represent tangle 2D, reflecting aspect propagation further relate it thereof. Method MCA represents neuroinformatics technique serving smooth out transitions...
Abstract Background Glial fibrillary acidic protein (GFAP) is a reactive astrogliosis biomarker, shown to increase in individuals with preclinical Alzheimer’s disease (AD). First thought be great marker of amyloid‐β (Aβ) pathology, recent post‐mortem research has linked it tau accumulation only. Here we investigate the independent associations plasma GFAP imaging markers AD along spectrum. Method 126 from TRIAD cohort underwent [ 18 F]MK6240 tau‐PET and F]AZD4694 Aβ‐PET assessment using an...